The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review

Curr Oncol. 2022 Sep 3;29(9):6350-6363. doi: 10.3390/curroncol29090500.

Abstract

Childhood and adolescent cancer survivors are disproportionately more likely to develop cardiovascular diseases from the late effects of cardiotoxic therapies (e.g., anthracycline-based chemotherapy and chest-directed radiotherapy). Currently, dexrazoxane is the only approved drug for preventing cancer treatment-related cardiac damage. While animal models highlight the beneficial effects of exercise cancer treatment-related cardiac dysfunction, few clinical studies have been conducted. Thus, the objective of this scoping review was to explore the designs and impact of exercise-based interventions for managing cancer treatment-related cardiac dysfunction in childhood and adolescent cancer survivors. Reviewers used Joanna Briggs Institute's methodology to identify relevant literature. Then, 4616 studies were screened, and three reviewers extracted relevant data from six reports. Reviewers found that exercise interventions to prevent cancer treatment-related cardiac dysfunction in childhood and adolescent cancer survivors vary regarding frequency, intensity, time, and type of exercise intervention. Further, the review suggests that exercise promotes positive effects on managing cancer treatment-related cardiac dysfunction across numerous indices of heart health. However, the few clinical studies employing exercise interventions for childhood and adolescent cancer survivors highlight the necessity for more research in this area.

Keywords: adolescent; cancer; cancer survivor; cardiotoxicity; exercise; pediatric.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthracyclines / adverse effects
  • Cancer Survivors*
  • Cardiotoxicity / etiology
  • Dexrazoxane* / therapeutic use
  • Heart Diseases* / chemically induced
  • Heart Diseases* / drug therapy
  • Humans
  • Neoplasms* / drug therapy
  • Survivors

Substances

  • Anthracyclines
  • Dexrazoxane

Grants and funding

This paper was not funded. However, the following authors are students supported in their programs via the stated funders. Stephanie Kendall is a trainee in the Cancer Research Training Program of the Beatrice Hunter Cancer Research Institute, with funds provided by Saunders Matthey. Jodi Langley is supported by the Beatrice Hunter Cancer Research Institute, funding provided by the Canadian Cancer Society’s Carol Ann Cole Graduate Studentship, and is a trainee in the Cancer Research Training Program. William Johnston is a trainee in the Cancer Research Training Program of the Beatrice Hunter Cancer Research Institute, with funds provided by CIBC.